J INTS BIO, AACR 2024 – ‘JIN-A02’, a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

11 Apr, 2024 by Theleaders-Online

Print this article Font size -16+

SEOUL, South Korea, April 11, 2024 /PRNewswire/ — J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8^th April poster session of the 2024 American Cancer Research Society (AACR) Annual Meeting held in San Diego, California, from 5^th to 10^th April (U.S. local time).

Professor Cho, Byoung Chul is having a conversation about the poster presentation of Phase 1/2 study of its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ at the 2024 American Association of Cancer Research in San Diego, USA (AACR 2024)

‘JIN-A02’ is a 4th generation EGFR-TKI targeting C797S mutation that causes resistance to 3rd generation EGFR-TKI (such as Osimertinib, Lazertinib), commonly used in the treatment of NSCLC. ‘JIN-A02’ also targets T790M mutation independently of C797S mutation.

This ongoing Phase 1 clinical study is currently in its 4^th Dose Level of 100mg daily and patients have showed increasing clinical benefits with each increasing dose levels. To-date, Partial Response (PR) was confirmed in one subject on the prior dose level of 50mg daily and stable diseases in two other subjects separately in Dose Level 50mg and 25mg daily.

J INTS BIO confirmed the favorable safety and efficacy signals of ‘JIN-A02’ with clinical benefits in this poster presentation in San Diego and greater clinical impact is expected as the study progresses.